[Evidence-based guideline for neonatal pain management in China (2023)]

    Insights

    This guideline provides evidence-based recommendations for neonatal pain management in China. It aims to standardize practices, reduce adverse effects, and improve neurodevelopmental outcomes for infants experiencing pain.

    Area of Science:

    • Neonatal care
    • Evidence-based medicine
    • Pain management

    Context:

    • Neonatal pain negatively impacts vital signs, homeostasis, and recovery.
    • Recurrent pain is a risk factor for neurodevelopmental disorders and chronic diseases.
    • Standardized pain management is crucial in Chinese neonatal wards.

    Purpose:

    • To standardize neonatal pain management practices in China.
    • To prevent and reduce adverse effects of pain on neonates' physical and mental development.
    • To provide guidance for medical staff on pain assessment and analgesia.

    Summary:

    • A multidisciplinary panel developed China's 2023 evidence-based guideline for neonatal pain management.
    • The guideline offers 26 recommendations across nine clinical areas, including assessment, non-pharmacological and pharmacological interventions, and parental involvement.
    • It follows WHO principles for guideline development, integrating best evidence and expert consensus.

    Impact:

    • Improves pain assessment and analgesia management for neonates.
    • Contributes to better neurodevelopmental outcomes and long-term health for infants.
    • Establishes a decision-making basis for healthcare professionals in neonatal pain care.